Liver transplantation in the era of non-alcoholic fatty liver disease/metabolic(dysfunction)associated fatty liver disease:the dilemma of the steatotic liver graft on transplantation and recipient survival  

作　　者：Seren M.Gedallovich Daniela P.Ladner Lisa B.VanWagner 

机构地区：[1]Division of Palliative Medicine,Department of Medicine,University of California San Francisco,San Francisco,CA,USA [2]Division of Organ Transplantation,Department of Surgery,Northwestern University Feinberg School of Medicine,Chicago,IL,USA [3]Division of Gastroenterology&Hepatology,Department of Medicine,Northwestern University Feinberg School of Medicine,Chicago,IL,USA [4]Division of Epidemiology,Department of Preventive Medicine,Northwestern University Feinberg School of Medicine,Chicago,IL,USA

出　　处：《Hepatobiliary Surgery and Nutrition》2022年第3期425-429,共5页肝胆外科与营养（英文）

基　　金：the National Heart,Lung,and Blood Institute(K23 HL136891 to LBV).

摘　　要：Liver transplantation remains the only curative therapy for end-stage liver disease and there is a well-established shortage of transplantable deceased donor organs to meet the growing demand of waitlisted patients.Steatotic liver grafts represent the most common type of so-called extended criteria donor(ECD)grafts aimed at ameliorating this disparity.However,steatotic grafts are associated with increased post-transplant complications and graft failure(1).Hepatic graft steatosis is strongly correlated with the high prevalence of non-alcoholic fatty liver disease(NAFLD)and metabolic(dysfunction)associated fatty liver disease(MAFLD)in the general population.NAFLD and MAFLD are related,but not equivalent,liver disorders that are linked with obesity and diabetes(2).Global prevalence of NAFLD is estimated at~25%and rising(3).Models predict that NAFLD prevalence will increase by 21%to affect 100.9 million persons worldwide by 2030(4).As more donors have NAFLD,the steatotic liver graft will continue to be a challenge for liver transplantation.But,promising efforts(e.g.,organ pump with defatting agents)are under way,aimed at expanding the donor pool in the coming years.Herein,we briefly summarize approaches for assessment of hepatic steatosis,describe recipient outcomes associated with the use of steatotic liver grafts,and highlight strategies that may be used to mitigate risk considering the ongoing NAFLD/MAFLD epidemic.

关 键 词：ORGANS GRAFT DONOR 

分 类 号：R57[医药卫生—消化系统]